Assessing BD OneFlow (TM) cost effectiveness in leukaemia diagnosis
Research type
Research Study
Full title
Evaluation of BD OneFlow™ flow cytometry reagent tubes for the diagnosis of patients with chronic lymphoid leukaemia
IRAS ID
196260
Contact name
Brigit Greystoke
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
BH153712, Newcastle University reference
Duration of Study in the UK
0 years, 4 months, 26 days
Research summary
If a doctor suspects a patient has a blood cancer such as leukaemia or lymphoma, they will send a blood sample to a hospital for specialised testing. This will include a test called flow cytometry. This involves analysing individual cells in the sample provided by the patient. This information is used by a haematologist (blood doctor) to decide if there are too many, or too few of a certain type of blood cell, or if there are any abnormal blood cells. A diagnosis is made according to which cells are abnormal. For example, if there are too many abnormal lymphocyte blood cells, a patient might have chronic lymphocytic leukaemia (CLL).
To be able to look at the cells in this way, the sample must be “stained” with chemicals mixed specifically for the cells expected in the sample. This is usually carried out by a highly trained scientist in the laboratory, but it takes a long time and the mixture needs to be checked carefully to make sure it contains the correct chemicals. A company called BD Biosciences has developed a dried, pre-prepared version of the chemicals used to detect CLL. In this study we will work out how using the BD Biosciences OneFlow™ test, instead of mixing chemicals, would affect the budget of the laboratory at the Royal Victoria Infirmary, Newcastle.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
16/NE/0369
Date of REC Opinion
22 Nov 2016
REC opinion
Favourable Opinion